Invests in biotechnology companies developing immunotherapies and targeted therapies for cancer treatment.
Portage Biotech Inc., headquartered in Tortola, British Virgin Islands, is a dynamic player in the pharmaceutical and biotechnology sectors, dedicated to advancing innovative therapies through rigorous research and development. The company specializes in a diverse portfolio of cutting-edge products designed to address critical medical needs. Notable among its offerings are IMM60, an iNKT cell activator, and IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine, both aimed at enhancing immune responses against various diseases, including cancers.
Portage Biotech Inc. also spearheads the development of TT-10, TT-4, TT-53, and TT-3, inhibitors targeting adenosine receptors to treat solid tumors and colorectal cancers. These therapies underscore the company's commitment to leveraging innovative approaches to combatting cancer by modulating key pathways in tumor growth and immune evasion. Additionally, the company's NT230-6, currently in Phase I/II clinical trials, represents a promising advancement in tumor treatment modalities.
Beyond its therapeutic pipeline, Portage Biotech Inc. employs advanced platforms such as Nanolipogel (NLG) for delivering DNA aptamers and aptamer-small molecule combinations, as well as a proprietary STING agonist platform. These technologies enhance immune activation and offer multifaceted approaches to stimulating anti-cancer immunity, positioning the company at the forefront of biotechnological innovation in oncology.